Neo-adjuvant chemo(radio)therapy in gastric cancer: Current status and future perspectives

Table 1 Pre-operative chemotherapy in non-resectable gastric cancer

Ref.	Regimen	No. patients	Stage	R0 resection (%)	Median survival (mo)
Wilkie et al[8]	EAP	34	NR	44	24
Plukker et al[9]	5-FU + MTX	20	NR	40	22
Rougier et al[10]	5-FU, P	30	NR	60	16
Kelsen et al[11]	FAMTX, IP 5FU-P	56	NR	61	15
Melcher et al[12]	ECF	27	R-NR	58 (R pts) 10 (NR pts)	10
Gallardo-Rincón et al[13]	P-ELF	60	NR	8,7	10
Cascinu et al[14]	EAFPLG	82	NR	45	17

NR: Non-resectable; EAP: Etoposide, doxorubicin, cisplatin; IP: Intraperitoneal; ECF: Epirubicin, cisplatin, 5-FU; R: Resectable; P-ELF: Cisplatin, etoposide, leucovorin, 5FU; EAPFLG: Epi-doxorubicin, 5-FU, cisplatin, leucovorin, glutathione; 5-FU: 5-fluorouracil.